The initial objective of this study was to evaluate for the first time the potential of cMLC-1 as a blood biomarker for TIC in breast cancer patients using plasma samples collected from HER2+ breast cancer patients, who had been treated with trastuzumab and either developed cardiotoxicity or did not. The gene discussed is ERBB2; the disease is breast cancer.